- Home
- ISPR vs IMA Comparison
ISPR vs IMA Comparison
Compare ISPR & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | IMA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6M | 92.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISPR | IMA |
|---|---|---|
| Price | $2.65 | $6.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $7.50 | ★ $16.00 |
| AVG Volume (30 Days) | 44.0K | ★ 63.8K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,506,875.00 | $800,000.00 |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $40.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $6.19 |
| 52 Week High | $6.38 | $18.00 |
Technical Indicators
Market Signals| Indicator | ISPR | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | N/A |
| Support Level | $2.37 | N/A |
| Resistance Level | $2.67 | N/A |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 91.47 | 0.00 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.